Aurinia Pharmaceuticals Inc (AUPH)

[CoolG73]

here is the link again, it is table 1

As for the 50% I mentioned in P3, this is aligned with global studies done previously (ALMS, Abatacept, to name few).
also check on clinical trial site, you can see the countries for P2 and those for P3, and you can clearly see the number of Hispanic and US sites go drastically up which means they are more focused on Black and Hispanic in P3.

a small adjustment to my statement earlier, I said 7 Hispanic were in P2, actually there were 9 in low dose VCS in P2, sorry for that I was writing from memory